ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028

As per Triton’s report, the Asia-Pacific companion diagnostics market is estimated to register growth at a CAGR of 13.10% during the forecast period 2022-2028.

Report scope can be customized per your requirements. Request For Customization

The countries assessed in the region include:

• China

• India

• Australia & New Zealand

• Japan

• South Korea

• ASEAN Countries

• Rest of Asia-Pacific

China captures the majority of the shares in the companion diagnostics market. The region’s market has witnessed substantial growth owing to the rise in precision medicine technology. The collaboration among pharmaceutical and diagnostics companies is also supporting the advancement in companion diagnostics. Furthermore, the rise in healthcare awareness and steady economic growth in various countries is expected to result in higher affordability of healthcare facilities. Such developments are expected to augment the growth of the companion diagnostics market over the upcoming years.

China has positioned itself as among the leading contributors in the in-vitro diagnostics segment over the past few years. This is mainly on account of high IVD adoption in cancer diagnostics. Additionally, the rising research activities in genome sequencing and high patient pool have created opportunities for market players in the companion diagnostics market to a large extent.

Furthermore, the increasing expertise in developing cost-effective sequencers created various opportunities for local vendors. For instance, companies like Shuwen Biotech and Simcere Diagnostics are contributing heavily to the companion diagnostics market.

Japan, on the other hand, is striving to increase the adoption of companion diagnostics. However, these are issues restraining faster approval of new CDx. For instance, the median delay is 21 months compared to the US regulatory environment. Nevertheless, the availability of reimbursement and approved CDx covered by the National Health Insurance is expected to create opportunities for the studied market.

The advent of next generation sequencing is expected to reduce the need for older techniques such as IHC and ISH. However, PCR techniques are expected to play a crucial role in the success of NGS technology. In this regard, PCR techniques in next-generation sequencing are integral as they permit the sequencing of multiple target regions. The market’s growth is assessed based on mechanism, consumer, indicator, and commodity. The mechanism section is divided into in-situ hybridization, next generation sequencing, polymerase chain reaction, immunohistochemistry, and other mechanisms.

Almac Group, Biocartis, Danaher Corporation, GE Healthcare, Genomic Health, Illumina Inc, and Myriad Genetics are some of the key companies profiled in the market.

Almac Group is engaged in diagnostics, formulation development, API services, clinical technologies, and commercial services. It also provides integrated services to companies operating in the pharmaceutical and biotechnology industries. Additionally, the company offers various biomarker solutions, including internal biomarker discovery, clinical trials, and unique discovery arrays. Almac has operations across the globe, including in the Asia-Pacific.

Key deliverables of the report:

● Market CAGR during the forecasting years 2022-2028

● Detailed data highlighting key insights, industry components, and market strategies

● Comprehensive information and estimation of the companion diagnostics market revenue growth in the Asia-Pacific and its influence on the parent market

● In-depth study of forthcoming trends in consumer behavioral patterns

● A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces

● A wide-ranging study of factors that will challenge the APAC companion diagnostics market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.

Major Players in the Market

Related Reports

Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT

Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT

Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT

Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagno ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET

2.2. KEY INSIGHTS

2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT

2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS

2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. KEY BUYING IMPACT ANALYSIS

2.4.1. COST

2.4.2. AVAILABILITY

2.4.3. SENSITIVITY & SPECIFICITY

2.4.4. EFFICACY

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.8. REGULATORY FRAMEWORK

2.9. KEY MARKET STRATEGIES

2.9.1. ACQUISITIONS

2.9.2. PRODUCT LAUNCHES

2.9.3. CONTRACTS & AGREEMENTS

2.10. MARKET DRIVERS

2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS

2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES

2.10.3. RISING PREVALENCE OF PRECISION MEDICINES

2.11. MARKET CHALLENGES

2.11.1. WEAK REIMBURSEMENT FRAMEWORK

2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS

2.12. MARKET OPPORTUNITY

2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING

3. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM

3.1. IN-SITU HYBRIDIZATION

3.2. POLYMERASE CHAIN REACTION

3.3. IMMUNOHISTOCHEMISTRY

3.4. NEXT GENERATION SEQUENCING

3.5. OTHER MECHANISMS

4. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR

4.1. ONCOLOGY

4.2. NEUROLOGY

4.3. INFECTIOUS DISEASES

4.4. OTHER INDICATORS

5. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER

5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

5.2. REFERENCE LABORATORIES

5.3. OTHER CONSUMERS

6. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY

6.1. ASSAY KITS AND REAGENTS

6.2. SOFTWARE AND SERVICES

7. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET - COUNTRY OUTLOOK

7.1. CHINA

7.2. JAPAN

7.3. INDIA

7.4. SOUTH KOREA

7.5. ASEAN COUNTRIES

7.6. AUSTRALIA & NEW ZEALAND

7.7. REST OF ASIA-PACIFIC

8. COMPETITIVE LANDSCAPE

8.1. ABBOTT LABORATORIES

8.2. ALMAC GROUP

8.3. ARUP LABORATORIES

8.4. BIOCARTIS

8.5. BIOMERIEUX

8.6. DANAHER CORPORATION

8.7. GE HEALTHCARE

8.8. GENOMIC HEALTH

8.9. ILLUMINA INC

8.10. MYRIAD GENETICS

8.11. QIAGEN

8.12. ROCHE DIAGNOSTICS

8.13. SYSMEX CORPORATION

8.14. THERMO FISHER SCIENTIFIC

8.15. AGILENT

9. RESEARCH METHODOLOGY & SCOPE

9.1. RESEARCH SCOPE & DELIVERABLES

9.2. SOURCES OF DATA

9.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: LIST OF ACQUISITIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF CONTRACTS & AGREEMENTS

TABLE 6: NUMBER OF CANCER PATIENTS IN 2020

TABLE 7: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: INDUSTRY COMPONENTS

FIGURE 3: FDA FRAMEWORK

FIGURE 4: CDX LEAKAGE POINTS

FIGURE 5: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)

FIGURE 6: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)

FIGURE 12: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)

FIGURE 17: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)

FIGURE 21: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 24: CHINA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 25: JAPAN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 26: INDIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 27: SOUTH KOREA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 28: ASEAN COUNTRIES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 29: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 30: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)